Completed PHASE3 INTERVENTIONAL 3-arm NCT01780428

Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain

A Double-Blind, Randomized, Placebo-Controlled, Multiple-dose Multi-Center Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain

Sponsor: Charleston Laboratories, Inc

Conditions Nausea Pain Vomiting

Interventions CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg) Placebo

Updated 7 times since 2017 Last updated: Nov 2, 2016 Started: Jan 31, 2013 Primary completion: Oct 31, 2013 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Nausea and Pain and is currently completed. Charleston Laboratories, Inc leads this study, which shows 7 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Apr 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Charleston Laboratories, Inc

Data source: Charleston Laboratories, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Philadelphia, United States